Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Essilor Carries out $300 Million US Private Placement Notes Issue on Favorable Terms



  Essilor Carries out $300 Million US Private Placement Notes Issue on
  Favorable Terms

Business Wire

CHARENTON-LE-PONT, France -- July 2, 2013

Regulatory News:

Essilor International (Paris:EI)is strengthening its financial position to
support ongoing implementation of its development strategy, with the goal of
improving the vision of 4.2 billion people worldwide.

To this end, the Company has carried out a $300 million US private placement
notes issue with 18 investors. The senior unsecured notes have been issued to
refinance a bank loan due in 2014. The issue will enable the Company to extend
the average maturity of its debt and broaden its investor base.

The program comprises five fixed or variable-rate tranches, with maturities
ranging between 2017 and 2023. The very favorable terms of the transaction
– with a 3.40% coupon rate offered on the 10-year tranche – attests to the US
investors’ confidence in Essilor’s financial strength. Initially announced as
a $150 million transaction, the issue was more than seven times
oversubscribed.

About Essilor

The world’s leading ophthalmic optics company, Essilor designs, manufactures
and markets a wide range of lenses to improve and protect eyesight. Its
corporate mission is to enable everyone around the world to access lenses that
meet his or her unique vision requirements. To support this mission, the
Company allocates more than €150 million to research and innovation every
year, in a commitment to continuously bring new, more effective products to
market. Essilor’s flagship brands are Varilux^®, Crizal^®, Definity^®,
Xperio^®, Optifog^TM and Foster Grant^®. It also develops and markets
equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of approximately €5 billion in 2012 and
employs around 50,700 people. It operates in some 100 countries with 22
plants, more than 400 prescription laboratories and edging facilities, as well
as several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in
the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Contact:

Essilor
Investor Relations and Financial Communication
Véronique Gillet – Sébastien Leroy – Ariel Bauer, +33 (0)1 49 77 42 16
or
Corporate Communication and Press
Maïlis Thiercelin, +33 (0)1 49 77 45 02
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement